Navigation Links
FDA Approves Astellas' Vaprisol(R) (Conivaptan Hydrochloride Injection) Premixed in 5% Dextrose for the Treatment of Hyponatremia
Date:10/22/2008

Arginine vasopressin (AVP) receptor antagonist now approved in single-use

premixed formulation

DEERFIELD, Ill., Oct. 22 /PRNewswire/ -- Astellas Pharma US, Inc. today announced that the U.S. Food and Drug Administration (FDA) has approved a new premixed formulation of Vaprisol: Vaprisol(R) (conivaptan hydrochloride injection) Premixed in 5% Dextrose. Discovered and developed by Astellas, Vaprisol, an arginine vasopressin (AVP) receptor antagonist, is the first and only approved drug indicated for the treatment of both euvolemic and hypervolemic hyponatremia in hospitalized patients. Hyponatremia is a potentially life-threatening condition that occurs when the body's blood sodium level falls significantly below normal. Vaprisol was originally approved by the FDA in an ampule formulation for the treatment of euvolemic hyponatremia in December 2005 and hypervolemic hyponatremia in February 2007.

The 100mL, single-use premixed formulation of Vaprisol comes in an INTRAVIA(R) Container, a product of Baxter Healthcare Corporation, containing 20 mg of conivaptan hydrochloride in 5% Dextrose solution. Lactic acid, USP is added for pH adjustment to pH 3.4 to 3.8. The new formulation will make preparation easier for health care providers as it is requires no measuring or mixing. Additionally, it has an expiration date of 24 months, six months longer than the original ampule formulation.

"Vaprisol Premixed in 5% Dextrose will be helpful in quickly preparing treatment for hyponatremia patients," said Dr. Joseph Verbalis, M.D., Professor of Medicine and Physiology at Georgetown University. "This ready-to- use product will be useful for hospitals and emergency rooms."

Hyponatremia is present in approximately 28 percent of patients upon admission into acute hospital care and another 14 percent acquire the condition while in acute care. Severe cases are medical emergencies that can result in swelling of the brain, respira
'/>"/>

SOURCE Astellas Pharma US, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related biology technology :

1. FDA Approves Orphan Drug Status for Revolutionary Cancer Drug for Children
2. FDA Approves AstraZenecas SEROQUEL XR(R) for the Treatment of Bipolar Depression and Bipolar Mania
3. FDA Approves Fougeras Clotrimazole Cream USP 1%
4. FDA Approves ALOXI(R) (Palonosetron HCl) Capsules for Prevention of Acute Chemotherapy-induced Nausea and Vomiting
5. USDA Approves Syngenta and John Deere for Broadened Biotechnology Endorsement for Corn Crop Insurance
6. Signalife Board Approves Merger
7. FDA Approves EOVIST(R) to Detect and Characterize Focal Liver Lesions
8. FDA Approves Abbotts XIENCE(TM) V Drug Eluting Stent
9. FDA Approves ACIPHEX(R) (rabeprazole sodium) 20 mg for Short-Term Treatment of GERD in Adolescents
10. FDA Approves CONCERTA(R) (methylphenidate HCI) Extended-release Tablets for Treatment of ADHD (Attention Deficit Hyperactivity Disorder) in Adults
11. FDA Approves Quark IND for DGFi, an siRNA Therapeutic Based on Silence Therapeutics Unique Proprietary Chemistry
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/15/2014)... "The interface is the device," Nobel laureate Herbert ... to be found at the junctures where layers ... of nanotechnology, the interfaces between layers of metal ... such high-tech favorites as spintronics, high-temperature superconductors, ferroelectrics ...
(Date:1/15/2014)... FALLS, N.Y., Jan. 15, 2014   Niagara Thermal Products ... by Buffalo BioBlower Technologies LLC ("B3") as the critical ... 2 award from the Army Corps of Engineers.  B3 ... kills all biological contaminants and destroys VOCs and other ...
(Date:1/15/2014)... England and SAN JOSE, California ... international biotechnology company developing antibody-drug conjugates for cancer, today announced ... Board of Directors. Dr Reynolds has over 20 years, development ... Medical Officer at Seattle Genetics. "I am delighted ...
(Date:1/15/2014)... IPSWICH, England , January 15, 2014 ... to win races on the Formula 1 track could help ... between McLaren Applied Technologies (MAT), Stowhealth (a GP surgery based ... funded by healthcare provider Simplyhealth. Telemetry technology, which ...
Breaking Biology Technology:A deeper look at interfaces 2Niagara Thermal Products LLC Selected as Critical Supplier for Buffalo BioBlower Air Purification Systems 2Oxford BioTherapeutics Appoints Thomas C Reynolds MD, PhD to its Board of Directors 2Oxford BioTherapeutics Appoints Thomas C Reynolds MD, PhD to its Board of Directors 3Formula 1 Technology Tackles Obesity in Unique Healthcare Partnership 2Formula 1 Technology Tackles Obesity in Unique Healthcare Partnership 3Formula 1 Technology Tackles Obesity in Unique Healthcare Partnership 4
... Oct. 24, 2011 Marshall Edwards, Inc. (Nasdaq: ... of novel therapeutics targeting cancer metabolism, announced today that Charles ... Company, has been appointed to its board of directors. The ... to six and the number of independent directors to five. ...
... (NYSE symbol: OME), a nutritional ingredient company and the ... fish meal products, today announced that it has retained ... with its omega-3 fish oil and omega-3 concentrate research ... analytical services and biotechnology consulting company that specializes in ...
... Oct. 24, 2011 Heart repair.  Bone repair. ...  Cerebral Palsy.  Diabetes.  Alzheimer,s.  Cystic Fibrosis.  Leukemia, Sickle ... metabolic disorders. "These diseases or group ... cured with umbilical cord blood stem cells or ...
Cached Biology Technology:Marshall Edwards Appoints Healthcare Investment Banking Veteran Charles Baltic to Board of Directors 2Marshall Edwards Appoints Healthcare Investment Banking Veteran Charles Baltic to Board of Directors 3Omega Protein Announces Retention of Lipid Technologies, LLC 2Cord Blood America Provides Insight on Worldwide Research Using Umbilical Cord Blood Stem Cells to Treat Numerous Diseases 2Cord Blood America Provides Insight on Worldwide Research Using Umbilical Cord Blood Stem Cells to Treat Numerous Diseases 3
(Date:4/22/2014)... club of a mantis shrimp, a team of researchers ... University of Southern California and Purdue University, have developed ... impact resistant and tougher than the standard used in ... this tiny crustacean, the more we realize its structure ... said David Kisailus, a Kavli Fellow of the National ...
(Date:4/22/2014)... Biology (FASEB) has released updated factsheets for ... National Institutes of Health (NIH) benefits each of the ... to make these factsheets available to help citizens and ... said FASEB President, Margaret K. Offermann, MD, PhD. NIH ... funding, investing $29.2 billion in FY 2013 in medical ...
(Date:4/22/2014)... begins a trip to Asia to coordinate with ... Pacific, officials at the Office of Naval Research ... Partnership (APTEP) as an example of strong and ... allies in the region. , The APTEP program, ... region, supports the development of alternative energy technologies. ...
Breaking Biology News(10 mins):Mantis shrimp stronger than airplanes 2Mantis shrimp stronger than airplanes 3Full power: Alternative energy partnerships flourish in Asia 2Full power: Alternative energy partnerships flourish in Asia 3
... CREEK, CAMessages from nearly a half-billion years ago, conveyed ... moss, provide clues about the earliest colonization of dry ... Joint Genome Institute (DOE JGI) was among the leaders ... to complete the first genome sequencing project of a ...
... published a paper today that is the most comprehensive ... are having on the worlds coral reefs. The ... and Ocean Acidification, co-authored by seventeen marine scientists from ... not survive the drastic increases in global temperatures and ...
... The Stowers Institutes Rong Li Lab, in collaboration ... quantitative in vivo measurement of the dynamic protein-protein ... signaling pathway, which is critical to growth and ... paper, Mapping Dynamic Protein Interactions in the MAP ...
Cached Biology News:DOE JGI Community Sequencing Program delivers first moss genome 2DOE JGI Community Sequencing Program delivers first moss genome 3Immediate action needed to save corals from climate change 2Immediate action needed to save corals from climate change 3Rong Li Lab reports protein interactions of MAP kinase signaling pathway 2
Physical Form: powder Color: white Removes FLAG peptide from N-terminal and Met-N-terminal fusion proteins. Supplied with optimized enterokinase buffer....
This antibody detects ubiquitinated proteins on SDS-PAGE immunoblots. It does not detect free ubiquitin....
... The Jouan B4i ventilated and BR4i refrigerated multifunction ... low speed operation at a low sound level ... certified for biocontainment. Their AUTO-LOCK rotor exchange system ... ready for use within seconds. Instant ...
... BR4i refrigerated multifunction centrifuges are equally capable of ... low sound level with a large range of ... rotor exchange system without tools ensures that the ... Instant rotor exchange (5 sec.) ...
Biology Products: